JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205

Volume 15 Issue 11, November 2025

Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

DISSEMINATED INTRAVASCULAR COAGULATION (DIC): PATHOGENESIS AND LABORATORY DIAGNOSIS

Tojiddinov Husniddin Salohiddinovich

Andijan State Medical Institute, Uzbekistan

Abstract: Disseminated intravascular coagulation (DIC) is a complex acquired syndrome characterized by widespread activation of the coagulation cascade, leading to microvascular thrombosis, consumption of clotting factors, and secondary hemorrhagic manifestations. It represents a final common pathway of various critical conditions, including sepsis, trauma, malignancy, obstetric complications, and severe inflammatory responses. This article reviews the pathogenesis of DIC with emphasis on the interplay between coagulation, platelets, endothelial dysfunction, and fibrinolysis. Additionally, it outlines key laboratory parameters essential for early recognition, diagnosis, and monitoring of the syndrome.

Keywords: disseminated intravascular coagulation, coagulopathy, microthrombosis, fibrin degradation, laboratory diagnosis.

Introduction

Disseminated intravascular coagulation is a life-threatening systemic disorder in which the balance between coagulation and fibrinolysis is lost, resulting in uncontrolled clot formation and progressive consumption of hemostatic components. It is not a primary disease but a secondary response to severe clinical conditions such as sepsis, obstetric complications, major trauma, severe tissue injury, and advanced malignancies. Early diagnosis is essential because DIC can rapidly progress to multiorgan dysfunction due to impaired microcirculation and extensive bleeding.

The complexity of DIC lies in its dual nature: while excessive thrombin generation promotes fibrin deposition within microvessels, depletion of clotting factors and platelets leads to hemorrhagic complications. Understanding the underlying mechanisms and identifying characteristic laboratory abnormalities are critical for timely management and improving survival outcomes.

Materials and Methods

This article is based on a descriptive analytical review of scientific literature, hematology textbooks, clinical guidelines, and laboratory data related to DIC. Comparative evaluation of published studies was used to summarize the pathophysiological mechanisms and diagnostic criteria. Laboratory markers commonly used in the diagnosis and monitoring of DIC were analyzed in accordance with international recommendations from the International Society on Thrombosis and Haemostasis (ISTH). Morphological descriptions were derived from studies

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 11, November 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

involving blood smears, coagulation tests, and fibrinolytic assays.

Results

Pathogenesis

The pathogenesis of DIC begins with excessive activation of the coagulation system, most commonly triggered by exposure of blood to tissue factor during inflammation, sepsis, trauma, or malignancy. This leads to uncontrolled thrombin generation and widespread fibrin deposition within the microvasculature. Endothelial injury amplifies these processes by increasing tissue factor expression, reducing anticoagulant pathways, and impairing fibrinolysis.

Natural anticoagulant mechanisms such as antithrombin, protein C, and protein S become depleted or functionally impaired. At the same time, levels of plasminogen activator inhibitor-1 rise, inhibiting fibrinolytic activity and allowing fibrin clots to persist. The persistent activation of coagulation results in consumption of platelets and clotting factors, producing thrombocytopenia and prolonged clotting times. Microvascular fibrin thrombi compromise tissue perfusion, contributing to organ ischemia and dysfunction.

Laboratory Diagnosis

The diagnosis of DIC relies on a combination of clinical findings and characteristic laboratory abnormalities. Key laboratory markers include:

Platelet Count: Platelet levels are typically decreased due to accelerated consumption within microthrombi. Progressive thrombocytopenia is a hallmark of evolving DIC.

Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT): Both are prolonged because of the depletion of coagulation factors. PT prolongation is often more pronounced.

Fibrinogen: Levels are usually reduced in DIC as fibrinogen is consumed during uncontrolled clot formation. However, in some inflammatory states, fibrinogen may be initially normal or elevated, later declining as DIC progresses.

D-Dimer and Fibrin Degradation Products (FDPs): Both are elevated due to accelerated fibrinolysis and breakdown of cross-linked fibrin. High D-dimer is one of the most sensitive markers for DIC.

Peripheral Blood Smear: Schistocytes (fragmented red blood cells) may be present due to mechanical damage within microthrombi, reflecting microangiopathic hemolytic processes.

Laboratory scoring systems, such as the ISTH DIC score, integrate platelet count, PT

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 11, November 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

prolongation, fibrinogen level, and D-dimer concentration to assess the probability and severity of DIC. Dynamic evaluation of these parameters over time is essential for accurate diagnosis and monitoring.

Discussion

The findings highlight that DIC is a systemic syndrome characterized by excessive coagulation activation and secondary fibrinolytic imbalance. The underlying triggers such as sepsis or obstetric complications determine the course and severity of DIC, but the pathological basis remains excessive thrombin production and fibrin deposition. Endothelial dysfunction plays a central role by amplifying tissue factor expression and impairing natural anticoagulant pathways.

Laboratory findings reflect the consumptive nature of the syndrome. Thrombocytopenia, prolonged coagulation times, reduced fibrinogen, and elevated D-dimer collectively reflect uncompensated hemostatic activation. Because no single test is diagnostic, a combination of laboratory indicators must be interpreted alongside clinical presentation. Early identification of laboratory trends is critical, as DIC may evolve rapidly and unpredictably.

Understanding the pathogenesis aids clinicians in selecting appropriate management strategies. Treatment focuses on addressing the underlying cause, supporting hemostasis, and preventing further microvascular thrombosis. In some cases, replacement therapy with fibrinogen, platelets, or coagulation factors may be required, whereas in severe thrombotic forms, anticoagulation may be indicated.

Conclusion

Disseminated intravascular coagulation is a profoundly complex and dynamic hemostatic disorder that arises as a final common pathway of multiple critical clinical conditions. Its pathogenesis reflects an intricate interplay between excessive coagulation activation, impaired anticoagulant defenses, endothelial dysfunction, and dysregulated fibrinolysis. The simultaneous occurrence of widespread microvascular thrombosis and consumptive coagulopathy represents the defining paradox of DIC, highlighting its dual nature as both a thrombotic and hemorrhagic syndrome.

The expanded understanding of DIC reveals that the syndrome is not a uniform entity but a spectrum that ranges from predominantly thrombotic forms, such as those associated with sepsis or trauma, to hemorrhagic presentations seen in late-stage consumption or obstetric catastrophes. Endothelial activation plays a central role, contributing to uncontrolled thrombin generation, suppression of natural anticoagulants, and inhibition of fibrinolytic pathways. Persistent microvascular fibrin deposition leads to tissue ischemia, organ dysfunction, and high mortality if not recognized and managed promptly.

The laboratory diagnosis of DIC remains essential for clinical decision-making. No single test

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 11, November 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

can diagnose the condition; rather, a comprehensive interpretation of multiple parameters is required. Markedly elevated D-dimer levels reflect accelerated fibrin formation and degradation, while prolonged PT and aPTT signal consumption of clotting factors. Progressive thrombocytopenia and decreasing fibrinogen levels further support the diagnosis. Serial monitoring provides additional prognostic value, as dynamic changes in laboratory markers often reflect the clinical course more accurately than absolute values.

A key conclusion from current evidence is that early recognition of laboratory abnormalities is crucial for preventing irreversible complications. Because DIC evolves rapidly, relying solely on clinical manifestations can delay intervention. Prompt identification and correction of the underlying cause—such as sepsis, obstetric complications, malignancy, or trauma—remains the cornerstone of therapy. Supportive measures, including judicious use of platelets, fibrinogen, cryoprecipitate, or anticoagulation in thrombotic forms, must be tailored to the patient's clinical presentation and laboratory profile.

Advancements in understanding the molecular mechanisms of DIC underscore the importance of personalized and targeted treatment strategies. Further research into endothelial biology, inflammatory pathways, and coagulation–fibrinolysis balance may open new avenues for early diagnosis, predictive modeling, and improved therapeutic interventions.

In summary, disseminated intravascular coagulation represents a critical, multifaceted disorder characterized by systemic coagulation activation, microvascular thrombosis, and consumptive bleeding. Comprehensive laboratory assessment and rapid clinical evaluation are essential for timely diagnosis and optimal management. As our understanding of DIC continues to evolve, improved diagnostic tools and therapeutic strategies hold promise for enhancing survival and reducing morbidity in affected patients.

Literatures:

1. Xamidov, A., Kholmirzayev, S., Rizayev, B., Umarov, I., Dadaxanov, F., & Muhtoraliyeva, M. (2022). The effectiveness of the use of monolithic reinforced concrete in the construction of residential buildings. *Science and innovation*, *1*(A8), 991-996.

2. Kurtieva, S. (2021). Adaptation capabilities of functional systems of the body of adolescents with vegetative dystonia syndrome. *International Journal of Health and Medical Sciences*, *4*(1), 129-135.

3. Nuralieva, D. M. (2020). CHARACTERISTICS OF MARRIAGE RELATIONS IN PROVIDING PSYCHOLOGICAL AID TO THE FAMILY AND IT INFLUENCE ON THE STRENGTH OF MARRIAGE. In *Психологическое здоровье населения как важный фактор обеспечения процветания общества* (pp. 411-414).

4. Kurtieva, S., Nazarova, J., & Mullajonov, H. (2021). Features of endocrine and immune status in adolescents with vegetative dystonia syndrome. *International journal of health*

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 11, November 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

sciences, *5*(2), 118-127.

5. Mukhitdinova, O., Alyavi, B. A., Ubaydullaeva, Z. Z., Uzokov, J. K., Mukhamedova, M. G., Rakhimova, D. A., ... & Orziev, D. Z. (2022). Changes of blood D-dimer level after COVID-19 in patients with coronary heart disease. *European Heart Journal: Acute Cardiovascular Care*, *11*(Supplement_1), zuac041-136.

6. Паттахова, М., Закирходжаев, Ш., & Салихов, М. (2021). Оценка пищевого статуса пациентов с хроническими заболеваниями печени и их диетическая коррекция.

7. Kurtieva, S., Nazarova, J., & Mullajonov, H. (2021). Features of Physical and Generative Development of Modern Teenagers Living in Uzbekistan. *NeuroQuantology*, *19*(7), 57-64.

8. Kurtieva, S. (2021). Clinical And Anamnestic Characteristics Of The Health State Of Adolescents With Vegetative Dysfunction Syndrome. *The American Journal of Medical Sciences and Pharmaceutical Research*, *3*(06), 1-12.

9. Rakhmatova, M., Shakhanova, S., Nazarova, J., Azizova, F., Astanakulov, D., Akramov, G., & Mirametova, N. (2024). Brain tumor information retrieval system for brain tumor diagnosis. *Health Leadership and Quality of Life*, (3), 10.

10. Karimov, B., Bekmetova, F., Doniyorov, S., Bekmetova, S., Ilkhomova, L., & Arslonov, S. (2024). The correlation between indicators of time intervals of left ventricular activity and markers of myocardial damage in patients with non-ST-segment elevation acute coronary syndrome. *Atherosclerosis*, *395*.

11. Nasirova, G. A., & Mukhamedova, M. G. (2023). Chronic heart failure and COVID-19. *International Journal of Scientific Research Updates*, *5*(1), 138-42.

12. Azizova, F. L., Ermatov, N. J., & Kutliev, J. A. (2022). HYGIENIC RECOMMENDATIONS FOR ORGANIZING A HEALTHY DIET TO INCR EASE THE PHYSICAL ACTIVITY OF MILITARY ATHLETES. *Art of Medicine. International Medical Scientific Journal*, *2*(1).

13. Куртиева, Ш., Иноятова, Ф. И., & Гафуров, Б. Г. (2021). ХОЗИРГИ ЗАМОН ЎСМИРЛАРИДА ФУНКЦИОНАЛ КАРДИОПАТИЯ СИНДРОМИНИ САБАБЛАРИ. *Журнал теоретической и клинической медицины*, (1), 39-42.

14. Azizova, F. (2019). *Imaddedin Nasimi in the Medieval Sources and Literary Criticism*. Teas Press.